Central Trust Company’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $323K | Sell |
5,845
-250
| -4% | -$13.5K | 0.01% | 510 |
|
|
2025
Q4 | $299K | Buy |
6,095
+33
| +0.5% | +$1.54K | 0.01% | 508 |
|
|
2025
Q3 | $262K | Sell |
6,062
-1,104
| -15% | -$43.1K | 0.01% | 539 |
|
|
2025
Q2 | $275K | Sell |
7,166
-340
| -5% | -$13K | 0.01% | 510 |
|
|
2025
Q1 | $291K | Sell |
7,506
-250
| -3% | -$9.15K | 0.01% | 488 |
|
|
2024
Q4 | $262K | Buy |
7,756
+414
| +6% | +$14.9K | 0.01% | 511 |
|
|
2024
Q3 | $300K | Buy |
7,342
+40
| +0.5% | +$1.64K | 0.01% | 484 |
|
|
2024
Q2 | $281K | Sell |
7,302
-626
| -8% | -$26.3K | 0.01% | 498 |
|
|
2024
Q1 | $340K | Sell |
7,928
-101
| -1% | -$4.17K | 0.01% | 482 |
|
|
2023
Q4 | $298K | Buy |
8,029
+245
| +3% | +$8.79K | 0.01% | 487 |
|
|
2023
Q3 | $282K | Sell |
7,784
-191
| -2% | -$6.78K | 0.01% | 493 |
|
|
2023
Q2 | $284K | Buy |
7,975
+268
| +3% | +$9.61K | 0.01% | 493 |
|
|
2023
Q1 | $274K | Sell |
7,707
-1,854
| -19% | -$64.9K | 0.01% | 487 |
|
|
2022
Q4 | $336K | Sell |
9,561
-4,780
| -33% | -$159K | 0.01% | 446 |
|
|
2022
Q3 | $422K | Buy |
14,341
+816
| +6% | +$30.9K | 0.01% | 402 |
|
|
2022
Q2 | $736K | Buy |
13,525
+3,924
| +41% | +$217K | 0.02% | 322 |
|
|
2022
Q1 | $523K | Buy |
9,601
+258
| +3% | +$14K | 0.02% | 402 |
|
|
2021
Q4 | $515K | Buy |
9,343
+1,150
| +14% | +$59.8K | 0.01% | 433 |
|
|
2021
Q3 | $392K | Buy |
8,193
+32
| +0.4% | +$1.61K | 0.01% | 448 |
|
|
2021
Q2 | $406K | Buy |
8,161
+720
| +10% | +$34.6K | 0.01% | 434 |
|
|
2021
Q1 | $332K | Sell |
7,441
-953
| -11% | -$43.3K | 0.01% | 438 |
|
|
2020
Q4 | $387K | Sell |
8,394
-240
| -3% | -$11K | 0.02% | 402 |
|
|
2020
Q3 | $407K | Sell |
8,634
-80
| -0.9% | -$4.01K | 0.02% | 362 |
|
|
2020
Q2 | $444K | Sell |
8,714
-320
| -4% | -$16.4K | 0.02% | 342 |
|
|
2020
Q1 | $428K | Sell |
9,034
-752
| -8% | -$40.1K | 0.03% | 329 |
|
|
2019
Q4 | $575K | Sell |
9,786
-2,340
| -19% | -$130K | 0.03% | 330 |
|
|
2019
Q3 | $647K | Sell |
12,126
-160
| -1% | -$8.23K | 0.04% | 301 |
|
|
2019
Q2 | $628K | Sell |
12,286
-67
| -0.5% | -$3.36K | 0.04% | 302 |
|
|
2019
Q1 | $645K | Buy |
12,353
+516
| +4% | +$25.8K | 0.04% | 289 |
|
|
2018
Q4 | $565K | Buy |
11,837
+131
| +1% | +$6.45K | 0.04% | 284 |
|
|
2018
Q3 | $588K | Sell |
11,706
-843
| -7% | -$42.8K | 0.03% | 312 |
|
|
2018
Q2 | $633K | Sell |
12,549
-694
| -5% | -$35K | 0.04% | 299 |
|
|
2018
Q1 | $647K | Sell |
13,243
-967
| -7% | -$45K | 0.04% | 297 |
|
|
2017
Q4 | $630K | Sell |
14,210
-3,462
| -20% | -$160K | 0.04% | 312 |
|
|
2017
Q3 | $897K | Sell |
17,672
-6,270
| -26% | -$318K | 0.06% | 250 |
|
|
2017
Q2 | $1.29M | Sell |
23,942
-2,309
| -9% | -$123K | 0.09% | 201 |
|
|
2017
Q1 | $1.38M | Sell |
26,251
-389
| -1% | -$19.7K | 0.09% | 187 |
|
|
2016
Q4 | $1.28M | Sell |
26,640
-6,462
| -20% | -$319K | 0.09% | 199 |
|
|
2016
Q3 | $1.78M | Sell |
33,102
-249
| -0.7% | -$13.7K | 0.13% | 161 |
|
|
2016
Q2 | $1.81M | Buy |
33,351
+755
| +2% | +$39.8K | 0.14% | 153 |
|
|
2016
Q1 | $1.65M | Sell |
32,596
-4,013
| -11% | -$200K | 0.13% | 159 |
|
|
2015
Q4 | $1.85M | Buy |
36,609
+2,108
| +6% | +$107K | 0.15% | 139 |
|
|
2015
Q3 | $1.66M | Buy |
34,501
+494
| +1% | +$25.7K | 0.14% | 143 |
|
|
2015
Q2 | $1.77M | Buy |
34,007
+1,597
| +5% | +$89.9K | 0.14% | 152 |
|
|
2015
Q1 | $1.87M | Buy |
32,410
+8
| +0% | +$459 | 0.15% | 143 |
|
|
2014
Q4 | $1.73M | Sell |
32,402
-8,226
| -20% | -$460K | 0.14% | 144 |
|
|
2014
Q3 | $2.33M | Sell |
40,628
-5,744
| -12% | -$352K | 0.19% | 130 |
|
|
2014
Q2 | $3.1M | Sell |
46,372
-1,650
| -3% | -$112K | 0.24% | 103 |
|
|
2014
Q1 | $3.21M | Sell |
48,022
-797
| -2% | -$53.9K | 0.27% | 92 |
|
|
2013
Q4 | $3.26M | Sell |
48,819
-1,883
| -4% | -$122K | 0.27% | 89 |
|
|
2013
Q3 | $3.18M | Buy |
50,702
+72
| +0.1% | +$4.63K | 0.29% | 86 |
|
|
2013
Q2 | $3.16M | Buy |
+50,630
| New | +$3.21M | 0.3% | 83 |
|
Other funds holding GSK
JEST
Central Trust Company's GSK Position: Q1 2026 in Review
Central Trust Company reduced its GSK (GSK) stake by 4.1% in Q1 2026, selling an estimated $13.5K and leaving 5,845 shares worth $323K. The position accounts for 0.01% of the portfolio, ranked #510.
Central Trust Company first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.26M in Q4 2013. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Central Trust Company held 5,845 shares of GSK worth $323K as of Q1 2026.
- Central Trust Company sold 250 GSK shares in Q1 2026, an estimated $13.5K.
- GSK made up 0.01% of Central Trust Company's portfolio in Q1 2026, its #510 holding.
- Central Trust Company first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
- Central Trust Company's GSK position peaked at $3.26M in Q4 2013.
- 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.